Skip to main content

Table 1 Clinicopathological features and the expression of nucleolin in 130 hepatocellular carcinoma patients

From: Increased level of nucleolin confers to aggressive tumor progression and poor prognosis in patients with hepatocellular carcinoma after hepatectomy

Clinicopathological features Case Nucleolin expression frequency (n,%) P
High Low
Age (years)     
≤50 72 40 (55.56) 32 (44.44) NS
>50 58 28 (48.28) 20 (51.72)
Gender     
Male 96 58 (60.42) 42 (39.58) NS
Female 34 20 (58.82) 14 (41.18)
Serum AFP     
Positive 72 58 (80.56) 14 (19.44) 0.008
Negative 58 20 (34.48) 38 (65.52)
Tumor stage     
T1 23 0 (0) 23 (100.00) 0.001
T2 40 23 (57.50) 17 (42.50)
T3 52 40 (76.92) 12 (23.08)
T4 15 15 (100.00) 0 (0)
Tumor grade     
G1 31 12 (38.71) 19 (61.29) 0.02
G2 76 48 (63.16) 28 (36.84)
G3 23 18 (78.26) 5 (21.74)
Growth pattern     
Trabecular 101 59 (58.42) 42 (41.58) NS
Nontrabecular 29 19 (65.52) 10 (34.48)
Cirrhosis     
Yes 86 50 (58.14) 36 (41.86) NS
No 44 28 (63.64) 16 (36.46)
Underlying liver disease     
Alcoholic 25 10 (40.00) 15 (60.00) NS
Hepatitis B 49 28 (57.14) 21 (42.86)
Hepatitis C 35 28 (80.00) 7 (20.00)
Unknown 21 12 (57.14) 9 (42.86)
  1. Note: `NS' refers to the differences among groups have no statistical significance.